The recent pull back in GHDX is primarily due to the much slower than expected growth in their OncotypeDX Node-Negative Breast cancer test. The ceo attributed this to the economy ($3,500 test) and the "distraction" of their recent colon cancer test launch. However, their OncotypeDX Node-Positive test did not experience the same "distraction". The ceo attributed this to the positive clinical trial data their node positive test has been receiving as of late.
This could be a buying opportunity or it may indicate larger management issues, imo, it may take another quarter to know which.
Interesting. Thanks for the response. I'm inclined to dig a little deeper into GHDX.
Market Data 
Markets 
AI
